



ESMO 2014 Industry Satellite Symposium

**Evolving Treatment Paradigms
for Advanced NSCLC:
Targeted Agents and Immunotherapeutics**

Monday 29 September 2014, 18.00–20.00
Granada Auditorium, Hall 10, IFEMA – Feria de Madrid, Madrid, Spain

AstraZeneca 

Evolving Treatment Paradigms for Advanced NSCLC: Targeted Agents and Immunotherapeutics

Chair: David Gandara (USA)

Date: Monday 29 September 2014, 18.00–20.00

Venue: Granada Auditorium, Hall 10, IFEMA – Feria de Madrid, Madrid, Spain

Personalising the treatment of resistance to EGFR-TKIs: what are the main challenges?

Geoffrey Oxnard (USA)

Treatment of other genomic subsets of NSCLC

Pasi Jänne (USA)

Toxicity profiles of emerging therapies for NSCLC

Silvia Novello (Italy)

Immune checkpoint blockade in NSCLC: combinations and optimal sequencing

Jean-Charles Soria (France)

Defining new clinical practice

David Gandara (USA)

Panel debate and audience Q&A

Faculty and audience